Ascletis' vision is to become the most innovative world-class biomedical company addressing global unmet medical needs in the area of metabolic diseases.
Our values guide us in how we do business and how we work together internally, and externally with our domestic and global partners.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist in development as a once-daily oral tablet and once-monthly subcutaneous injection for weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, ......
Ascletis Announces Poster Presentations on the Study Results of Oral Small Molecule G......
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Da......
Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.
Ascletis' vision is to become the most innovative world-class biomedical company addressing global unmet medical needs in the area of metabolic diseases.
We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to hr@ascletis.com. We will look to match any current and upcoming openings to your area of expertise.
© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号
浙ICP备11050387号-1
